Novel prodromal biomarkers that are symptomatic of injury require histopathologic or clinical chemistry anchors to characterize activity

J Pharmacol Toxicol Methods. 2009 Nov-Dec;60(3):321-2. doi: 10.1016/j.vascn.2009.07.005. Epub 2009 Jul 24.

Authors

Josef S Ozer¹, Aaron Teitelbaum

Affiliation

¹ Pfizer Global Research and Development, Pharmacokinetics, Dynamics, and Metabolism, 700 Chesterfield Parkway West, T2A, Chesterfield, MO 63017, USA. josef.ozer@pfizer.com

PMID: 19632346
DOI: 10.1016/j.vascn.2009.07.005

No abstract available

Publication types

Review

MeSH terms

Acute Disease
Animals
Biomarkers* / metabolism
Biomarkers* / urine
Chemistry, Clinical* / methods
Chemistry, Clinical* / standards
Homovanillic Acid / urine
Humans
Kidney Diseases / etiology*
Kidney Diseases / metabolism*
Kidney Diseases / pathology
Kidney Diseases / urine

Substances

Biomarkers
Homovanillic Acid